Cholestyramine NDC 68094-906

NDC codes

FDA NDC Directory

Product NDC (as listed)68094-906Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68094-0906Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68094-906-10	68094090610	201.6 g in 1 CAN (68094-906-10)Marketed from Dec 15, 2023
68094-906-20	68094090620	60 POUCH in 1 CARTON (68094-906-20) / 4.8 g in 1 POUCHMarketed from Dec 15, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cholestyramine
Generic name (nonproprietary): cholestyramine
Active ingredients: Cholestyramine — 4 g/4.8g
Dosage form: Powder, For suspension
Route: Oral
Labeler: Precision Dose, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209599
Marketing start: Dec 15, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 68094-906_37093f43-91d8-424c-98d9-8a07334454adSPL ID 37093f43-91d8-424c-98d9-8a07334454adSPL set ID 129fa522-b66b-4bb1-9ac6-74f98d93a86fRxCUI 1801279UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468094090610 followed by a unit qualifier and the quantity

Package 68094-0906-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 20, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Cholestyramine for oral suspension USP, light is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP, light may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular dise…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209599

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209599
Product	Strength	Form · route	Labeler	Product NDC
Cholestyramine Lightcholestyramine	Cholestyramine 4 g/4.8g	Powder, For suspensionOral	TAGI Pharma, Inc.	51224-009